ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in
combination with ZD1839, that can be given safely to children and to learn the good and bad
effects. Studies performed in the laboratory have shown that ZD1839 helps make available the
orally administered irinotecan. In this study the intravenous (given into the vein) formula
of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a
fixed dose and will be administered orally on days 1-12. Each course of treatment will
consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of
course 2 will be an intravenous administration. All other doses and subsequent courses will
consist of an orally administered dose.